Invasive aspergillosis in patients with hematological malignancies in the Czech and Slovak republics: Fungal InfectioN Database (FIND) analysis, 2005–2009

Ráčil, Zdeněk; Weinbergerová, Barbora; Kocmanová, Iva; Mužı́k, Jan; Kouba, Michal; Drgoňa, Ľuboš; Masárová, Lucia; Guman, Tomáš; Tóthová, Elena; Forsterová, Kristina; Haber, Jan; Žiaková, Barbora; Bojtárová, Eva; Vydra, Jan; Múdrý, Peter; Foralová, Renata; Sejnová, Daniela; Mallátová, Naďa; Kandrnal, Vít; Cetkovský, Petr; Mayer, Jiřı́

doi:10.1016/j.ijid.2012.09.004

Cited by 18 publications

(10 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…BAL was performed in 69% of the patients with a lower respiratory tract involvement. This rate is high compared to published data and facilitated the identification of pulmonary coinfections in our cohort [24,25]. These data confirm the critical role of BAL in the investigation of pulmonary CT abnormalities in immunocompromised patients; it improved the accurate diagnosis rate of pulmonary IA, with one in five cases diagnosed by BALF analysis only, and identified co-pathogens.…”

Section: Discussionsupporting

confidence: 85%

Factors associated with coinfections in invasive aspergillosis: a retrospective cohort study

Danion¹,

Duval²,

Séverac³

et al. 2021

Clinical Microbiology and Infection

View full text Add to dashboard Cite

Objectives: To describe the coinfections in invasive aspergillosis (IA), to identify factors associated with coinfections, and to evaluate the impact of coinfection on mortality. Patients and methods: We conducted a monocentric retrospective study of consecutive putative, probable, or proven IA that occurred between 1997 and 2017. All coinfections, with an onset within 7 days before or after the first sign of aspergillosis, were identified. Factors associated with coinfections and mortality were analysed by multivariable analysis.Preliminary results have been presented as an oral communication at ECCMID 2019.

show abstract

Section: Discussionsupporting

confidence: 85%

Factors associated with coinfections in invasive aspergillosis: a retrospective cohort study

Danion¹,

Duval²,

Séverac³

et al. 2021

Clinical Microbiology and Infection

View full text Add to dashboard Cite

show abstract

“…However, the GM result in BAL fluid for A. flavus in our study (28/116, 24.1 %) is not comparable to the results from The Netherlands (3.44 %) [47], Italy (4.5 %) [48], USA (0.8 and 1.2 %) [36,39], Belgium (2.3 %) [7], France (2 %) [49], UK (0.6 %) [50], China (4 %) [33], Japan (0.6 %) [22], Czech and Slovak Republics (4.2 %) [51], Turkey (3.3 %) [52] and India (11.6 %) [46]. To the best of our knowledge, none of the previous studies reported a twofold mean of the GM index in IA patients with A. fumigatus in comparison to IA patients with A. flavus.…”

Section: Discussionsupporting

confidence: 82%

Effect of involved Aspergillus species on galactomannan in bronchoalveolar lavage of patients with invasive aspergillosis

Armaki

Hedayati

Moqarabzadeh

et al. 2017

Journal of Medical Microbiology

View full text Add to dashboard Cite

Purpose. The detection of galactomannan (GM) in bronchoalveolar lavage (BAL) fluid is an important surrogate marker for the early diagnosis and therapeutic monitoring of invasive aspergillosis (IA), regardless of the involved species of Aspergillus. Here, we utilized the Platelia Aspergillus GM enzyme immunoassay (Bio-Rad) to evaluate the GM index in BAL fluid samples from patients with proven, probable or putative IA due to Aspergillusflavus versus Aspergillusfumigatus.Methodology. In a prospective study between 2009 and 2015, 116 BAL samples were collected from suspected IA patients referred to two university hospitals in Tehran, Iran.Key findings. According to European Organization for Research and Treatment of Cancer and Mycoses Study Group and Blot criteria, 35 patients were classified as IA patients, of which 33 cases tested positive for GM above 0.5 and, among these patients, 22 had a GM index !1. Twenty-eight were culture positive for A. flavus and seven for A. fumigatus. The GM index for A. flavus cases was between 0.5-6.5 and those of A. fumigatus ranged from 1 to 6.5. The sensitivity and specificity of a GM index !0.5 in cases with A. flavus were 86 and 88 % and for A. fumigatus patients were 100 and 73 %, respectively.Conclusion. Overall, the mean GM index in patients with A. fumigatus (3.1) was significantly higher than those of A. flavus (1.6; P-value=0.031) and the sensitivity of GM lower for A. flavus when compared to A. fumigatus. This finding has implications for diagnosis in hospitals and countries with a high proportion of A. flavus infections.

show abstract

“…In contrast Wingard's study evaluating prophylaxis with fluconazole and voriconazole in stem cell transplant patients and also another recently published study did not show any influence of mould‐active prophylaxis on GM positivity rate . Study design in the latter studies, however, differed markedly from Marr′s study as they both were primarily focussing on other objectives.…”

Section: Discussionmentioning

confidence: 82%

Sensitivity of galactomannan enzyme immunoassay for diagnosing breakthrough invasive aspergillosis under antifungal prophylaxis and empirical therapy

Hoenigl

Seeber

Koidl

et al. 2013

Mycoses

View full text Add to dashboard Cite

Data on diagnostic performance of Galactomannan (GM) testing in patients under mould-active regimens are limited. Whether sensitivity of GM testing for diagnosing breakthrough invasive aspergillosis (IA) is decreased under antifungal prophylaxis/therapy remains therefore a point of discussion. We retrospectively analysed GM test results in patients who were admitted with underlying haematological malignancies to two Divisions of the Medical University Hospital of Graz, Austria, between 2009 and 2012. Only cases of probable and proven IA that were diagnosed by other methods than GM testing were included (time of diagnosis = day 0). We compared GM results of patients with/without therapy/prophylaxis for the period of 2 weeks prior (week -2) until 3 weeks postdiagnosis. A total of 76 GM test results in nine patients were identified. Six patients had received antifungal therapy/prophylaxis from week -2, whereas three patients were treated with therapy from the time of diagnosis at week 0. GM testing was positive in 45/76 (59%) of samples. Sensitivity of GM testing for detection of proven or probable IA at week -1 and 0 was 77% and 79% in patients with mould-active regimens. We conclude that GM testing might be a useful diagnostic method for breakthrough IA in patients receiving mould-active prophylaxis/therapy.

show abstract

Invasive aspergillosis in patients with hematological malignancies in the Czech and Slovak republics: Fungal InfectioN Database (FIND) analysis, 2005–2009

Abstract: Our retrospective analysis identified key diagnostic and treatment characteristics, and this understanding could improve the management of hematological malignancy patients with IA.

Cited by 18 publications

References 34 publications

Factors associated with coinfections in invasive aspergillosis: a retrospective cohort study

Factors associated with coinfections in invasive aspergillosis: a retrospective cohort study

Effect of involved Aspergillus species on galactomannan in bronchoalveolar lavage of patients with invasive aspergillosis

Sensitivity of galactomannan enzyme immunoassay for diagnosing breakthrough invasive aspergillosis under antifungal prophylaxis and empirical therapy

Contact Info

Product

Resources

About